Skip to main content
Stephen Gottschalk, MD, Pediatric Hematology & Oncology, Memphis, TN

Stephen Gottschalk MD

Pediatric Hematology & Oncology•Memphis, TN

Chair, Dept of BMT & Cellular Therapy, St Jude Children's Research Hospital

Join to view full profile

  • 262 Danny Thomas PlMemphis, TN 38105

  • Phone+1 901-595-3300

  • Fax+1 901-595-3842

Dr. Gottschalk is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Gottschalk's full profileAlready have an account?

Education & Training

  • Baylor College of Medicine
    Baylor College of MedicineFellowship, Pediatric Hematology/Oncology, 1998 - 2001
  • Baylor College of Medicine (Houston)
    Baylor College of Medicine (Houston)Residency, Pediatrics, 1995 - 1998
  • University of Gottingen Faculty of Medicine
    University of Gottingen Faculty of MedicineClass of 1992

Certifications & Licensure

  • TN State Medical License
    TN State Medical License 2017 - 2027
  • TX State Medical License
    TX State Medical License 2001 - 2026
  • Pediatric Hematology-Oncology
    American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • EBV/LMP-specific T Cells Maintain Remissions of T and B Cell EBV Lymphomas After Allogeneic Bone Marrow Transplantation  
    Stephen Gottschalk, Rayne Rouce, Catherine M Bollard, Helen E Heslop, Blood

Abstracts/Posters

  • CD70-Specific CAR T Cells Have Potent Activity Against Acute Myeloid Leukemia (AML) without HSC Toxicity
    Stephen Gottschalk, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Lentiviral Gene Therapy with Low Dose Busulfan for Infants with X-SCID Results in the Development of a Functional Normal Immune System: Interim Results of an Ongoing P...
    Stephen Gottschalk, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Inducible MyD88 Signaling Enhances the Anti-AML Activity of BiTE-Secreting ENG T-Cells
    Stephen Gottschalk, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

  • The Landscape of CART Beyond ALL. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Press Mentions

  • HMN 2025: How X-SCID Gene Remedy Offers Scientists a Uncommon Glimpse into Early Immune System
    HMN 2025: How X-SCID Gene Remedy Offers Scientists a Uncommon Glimpse into Early Immune SystemAugust 1st, 2025
  • Fundamental Research Sets the Stage for Immuno-Oncology Collaboration
    Fundamental Research Sets the Stage for Immuno-Oncology CollaborationJune 26th, 2025
  • Researchers Develop mRNA-Based CAR-T Therapy to Create Living Anti-Cancer Agents
    Researchers Develop mRNA-Based CAR-T Therapy to Create Living Anti-Cancer AgentsJune 20th, 2025

Grant Support

  • T32 Training Program in Pediatric Immuno-Oncology and ImmunotherapyST. JUDE CHILDREN'S RESEARCH HOSPITAL2022–2027
  • T32 Training Program in Pediatric Immuno-Oncology and ImmunotherapyST. JUDE CHILDREN'S RESEARCH HOSPITAL2022–2027
  • Enhancing B7-H3-CAR T cell therapy for pediatric solid tumorsST. JUDE CHILDREN'S RESEARCH HOSPITAL2022–2026

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Stephen Gottschalk, Dr. Stephen Gottschalk, MD, Dr. S Gottschalk